Analysed YD BIO LTD (YDES:NASDAQ) News Sources
YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States
31-03-2026
yahoo.com
YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem
17-03-2026
yahoo.com
YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform
25-02-2026
yahoo.com
YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy
29-01-2026
yahoo.com
YDES: YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations.
13-01-2026
yahoo.com
YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development
06-01-2026
yahoo.com
YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap
05-01-2026
yahoo.com
YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center
16-12-2025
yahoo.com
What is the current price of YD BIO LTD (YDES:NASDAQ)?
The current price of YD BIO LTD (YDES:NASDAQ) is $6.26.
YD BIO LTD (YDES:NASDAQ) absolute price change since previous trading day?
The absolute price change of YD BIO LTD (YDES:NASDAQ) since the previous trading day is $0.48.
YD BIO LTD (YDES:NASDAQ) percentage price change since previous trading day?
The percentage price change of YD BIO LTD (YDES:NASDAQ) since the previous trading day is 8.3045%.
What is the most recent average sentiment score for YD BIO LTD (YDES:NASDAQ)?
The most recent average sentiment score for YD BIO LTD (YDES:NASDAQ) is 80 out of 100.
What is the most recent average sentiment for YD BIO LTD (YDES:NASDAQ)?
The most recent sentiment for YD BIO LTD (YDES:NASDAQ) is .
SEC-8K** Filing Available For YD BIO LTD (YDES:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.